NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Alkem Laboratories delivered a strong FY26 performance with total revenue growing 13.5% YoY to ₹14,712 crore and EBITDA surpassing the ₹3,000 crore milestone with a 20.4% margin. A key highlight was the successful March 2026 launch of Semaglutide (GLP-1), which quickly secured an 11% unit market share. While domestic chronic segments outperformed the market with 16.1% growth, the company faces upcoming headwinds including a significant tax rate hike in FY27 and the departure of CEO Dr. Vikas Gupta. Management is prioritizing the integration of the Occlutech acquisition and expects no further M&A for the next 12 months.
முக்கிய அம்சங்கள்
Annual EBITDA reached a record ₹3,052 crore with margins expanding to 20.4% from 19.4% in FY25.Semaglutide launch in March 2026 achieved 11% unit market share according to latest IQVIA data.Chronic segment grew 16.1% YoY, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 13.6%.International business delivered robust growth of 22.5% YoY, supported by new launches and market expansion.Q4 FY26 revenue stood at ₹3,603 crore (+14.6% YoY) despite exceptional impairment charges of ₹74.7 crore in real estate.
👀 கவனிக்க வேண்டியவை
Investors should remain bullish on Alkem's successful pivot toward high-growth chronic therapies and GLP-1 drugs, but must factor in a higher effective tax rate and potential margin pressure from rising API costs in FY27.
Alkem Reports Record FY26 EBITDA of ₹30,052 Mn; Q4 Revenue Up 14.6% YoY
Alkem Laboratories delivered a strong operational performance in FY26, achieving its highest-ever EBITDA of ₹30,052 million with a margin of 20.4%. Q4FY26 revenue grew 14.6% YoY to ₹36,033 million, though net profit for the quarter fell 22.7% to ₹2,365 million due to exceptional charges of ₹1,350 million. The company maintains a robust net cash position of ₹54.74 billion and continues to outperform the Indian Pharmaceutical Market (IPM) across key chronic and acute therapies.
முக்கிய அம்சங்கள்
Record annual EBITDA of ₹30,052 million in FY26, representing a 19.6% YoY growth.International business grew 22.5% in FY26, with US sales reaching ₹29,845 million (+20.3% YoY).Domestic business outperformed the IPM by 100 bps in Q4, led by 250 bps outperformance in the chronic segment.Exceptional items of ₹1,748 million for FY26 included labor code-related gratuity costs and real estate impairments.Strong balance sheet with net cash of ₹54.74 billion as of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should look past the Q4 PAT decline as it was driven by one-time exceptional items; the core operational metrics and margin expansion remain healthy. Monitor the regulatory response for the Daman facility which received 7 observations in April 2026.
Alkem Labs Approves FY26 Results, Recommends Rs 10 Final Dividend
Alkem Laboratories has approved its audited financial results for the quarter and fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 10 per equity share (500% of face value), with a record date of August 7, 2026. Additionally, the company announced the re-appointment of Mrs. Madhurima Singh as Executive Director for a five-year term starting December 2026. The auditors have provided an unmodified opinion on the financial statements, ensuring reporting reliability.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 10 per equity share of Rs 2 face value for FY 2025-26.Fixed August 7, 2026, as the record date for dividend eligibility and August 27, 2026, for the AGM.Re-appointed Mrs. Madhurima Singh as Executive Director for a 5-year term (Dec 2026 to Dec 2031).Auditors issued an unmodified opinion on both standalone and consolidated financial results.Dividend payment is scheduled to commence from September 1, 2026, subject to shareholder approval.
👀 கவனிக்க வேண்டியவை
Investors should monitor the stock for dividend eligibility before the August 7 record date. The unmodified audit report and management continuity are positive indicators of corporate governance and stability.
Alkem Laboratories Taloja CRO Facility Clears US FDA Inspection with Zero Observations
Alkem Laboratories announced that its Clinical Research Organization (CRO) facility in Taloja, Maharashtra, underwent an unannounced US FDA inspection on May 08, 2026. The inspection concluded successfully with no Form 483 observations being issued by the regulator. This clean report signifies high compliance with international quality standards for clinical research. Such regulatory clearances are vital for maintaining the integrity of data used in US drug filings and product approvals.
முக்கிய அம்சங்கள்
US FDA conducted an unannounced inspection at the Taloja CRO facility on May 08, 2026.The inspection concluded with zero Form 483 observations issued to the company.The facility serves as a key Clinical Research Organization (CRO) for Alkem's global filings.Successful compliance ensures no delays in product pipelines related to this facility's research data.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that mitigates regulatory risk; no action is required other than monitoring upcoming product approvals.
Alkem Labs Receives Favourable GST Order; Demand and Penalty of ₹139.3 Cr Dropped
Alkem Laboratories has received a favourable Order-in-Appeal from the Commissioner (Appeals) - II CGST & C.Ex, Mumbai, regarding a tax dispute. The order successfully drops a GST demand of ₹69.66 crore along with an equivalent penalty of ₹69.66 crore. The dispute was related to alleged incorrect availment of Input Tax Credit (ITC) and GST refunds. This resolution removes a combined potential liability of approximately ₹139.3 crore plus applicable interest from the company's books.
முக்கிய அம்சங்கள்
Favourable Order-in-Appeal passed by Commissioner (Appeals) - II CGST & C.Ex, Mumbai.GST demand of ₹69,65,52,636 (~₹69.66 crore) has been completely dropped.Penalty of ₹69,65,52,636 (~₹69.66 crore) previously imposed has been set aside.Total potential financial liability resolved exceeds ₹139.3 crore excluding interest.The order pertains to allegations of incorrect ITC availment and GST refund payments.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that eliminates a significant contingent liability. No further action is required as the ruling settles a potential financial risk in the company's favour.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Alkem Labs Receives 7 US FDA Observations for Amaliya, Daman Facility
Alkem Laboratories has received a Form 483 with seven observations from the US FDA following an inspection at its Amaliya, Daman manufacturing plant. The inspection was conducted over a 12-day period from April 20, 2026, to May 1, 2026. The company has committed to addressing these observations within the stipulated timeframe to ensure compliance. Regulatory hurdles at manufacturing sites can potentially delay new product approvals and impact export revenues to the US market.
முக்கிய அம்சங்கள்
US FDA inspection conducted at Amaliya, Daman facility from April 20 to May 1, 2026Issuance of Form 483 with 7 distinct observations at the end of the auditCompany to submit a response and address observations within the required timelineThe Amaliya facility is a key manufacturing site for Alkem's international operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's progress in resolving these observations and watch for any classification as Official Action Indicated (OAI). Expect short-term pressure on the stock price until the severity of the observations is clarified.
Alkem Labs Receives ₹333.38 Cr Income Tax Order; No Immediate Cash Outflow
Alkem Laboratories has received an assessment order for AY 2023-24 from the Income Tax Department with a disputed tax amount of ₹333.38 Crores. The order involves disallowances related to Section 80IE deductions and transfer pricing adjustments. Importantly, the company has clarified that there is no immediate cash outflow required as the demand will be adjusted against available MAT credits. Alkem intends to contest the order through an appeal, asserting that the claims are not legally tenable.
முக்கிய அம்சங்கள்
Income Tax authority issued an order for AY 2023-24 with a disputed amount of ₹333.38 Crores.Dispute stems from partial disallowance of Section 80IE deductions and transfer pricing adjustments.No immediate cash impact on the company due to the utilization of available MAT credits.Alkem Laboratories plans to file an appeal against the order, citing strong factual and legal grounds.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the appeal process as a favorable ruling would preserve MAT credits for future tax liabilities. No immediate impact on liquidity or operations is expected.
Alkem Laboratories CEO Dr. Vikas Gupta Resigns; Transition to Continue Until June 30, 2026
Alkem Laboratories has announced the resignation of its Chief Executive Officer, Dr. Vikas Gupta, effective June 30, 2026. Dr. Gupta is stepping down to pursue new professional opportunities after serving as a Key Managerial Personnel. The company has established a transition period of approximately two months to ensure operational continuity. Investors will be closely watching for the announcement of a successor to lead the pharmaceutical major.
முக்கிய அம்சங்கள்
Dr. Vikas Gupta resigned as CEO and Key Managerial Personnel on April 24, 2026.The executive will continue in his current role until June 30, 2026, for a smooth transition.The resignation is intended to allow the outgoing CEO to pursue other professional opportunities.The company has not yet named a successor to the CEO position in this disclosure.
👀 கவனிக்க வேண்டியவை
Investors should monitor upcoming board meetings for the appointment of a new CEO to gauge future strategic direction. Maintain a watch on the stock for any volatility resulting from leadership uncertainty during the transition period.
Alkem Laboratories Sets Up Dubai Subsidiary with AED 3.67 Million Capital for Global Exports
Alkem Laboratories has incorporated a wholly owned subsidiary (WOS) named Alkem Pharma Trading FZCO in Dubai, UAE. The subsidiary has been established with an authorized and subscribed share capital of AED 3,670,000, consisting of 3,67,000 equity shares. This move is strategically aimed at boosting the company's export capabilities to African, South East Asian, and other non-UAE international markets. The incorporation was finalized following the receipt of the Certificate of Formation from the Dubai Airport Free Zone Authority on April 13, 2026.
முக்கிய அம்சங்கள்
Incorporation of 100% Wholly Owned Subsidiary (WOS) Alkem Pharma Trading FZCO in Dubai, UAE.Total cash investment for share subscription amounts to AED 3,670,000 (approx. 3.67 million AED).Strategic focus on expanding export reach into Africa and South East Asian markets.The subsidiary's capital is divided into 3,67,000 equity shares with a face value of AED 10 each.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's export growth trajectory in the African and SE Asian regions as this subsidiary becomes operational. This expansion is a positive indicator of Alkem's intent to diversify its geographic revenue base.
Alkem Labs Doubles Investment to INR 1,036 Crores for New Ujjain Manufacturing Facility
Alkem Laboratories has announced a significant upward revision in its capital expenditure for a new greenfield formulations plant in Ujjain, Madhya Pradesh. The Board of Directors has approved increasing the investment from the previously planned INR 533 crores to INR 1,036 crores. This investment will be deployed in a phased manner on a 30-acre land parcel. The doubling of the budget suggests a larger scale of operations or more advanced technology integration than initially planned.
முக்கிய அம்சங்கள்
Investment for Ujjain facility increased from INR 533 crores to INR 1,036 croresSetting up a greenfield formulations manufacturing facility on 30 acres of landLand allotted by DMIC Vikram Udyogpuri Limited in Phase-2, UjjainCapital deployment to be executed in a phased mannerExpansion follows the initial land allotment approval dated March 18, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong signal of long-term growth and capacity building. Monitor future management commentary regarding the expected timeline for commissioning and the specific therapeutic segments this facility will serve.
Alkem Launches Semaglutide Injection in India at INR 450 per Week
Alkem Laboratories has launched indigenously-developed Semaglutide injections in India for type-2 diabetes and chronic weight management. The product is priced aggressively at INR 1,800 per month (INR 450 per week), aiming to significantly lower the entry barrier for GLP-1 therapy. The company received DCGI approval following successful Phase 3 clinical trials in India. This launch strengthens Alkem's position in the high-growth chronic therapy segment, leveraging its extensive distribution network.
முக்கிய அம்சங்கள்
Launched Semaglutide under brand names Semasize, Obesema, and Hepaglide for diabetes and weight lossDisruptive pricing at INR 450 per week compared to significantly higher costs for imported alternativesReceived DCGI approval for manufacturing and marketing after completing Phase 3 clinical trials in IndiaIntroduced both pre-filled disposable pens and reusable injection pens for higher maintenance dosesTargets the chronic therapy market where Alkem is currently the 6th largest player in India
👀 கவனிக்க வேண்டியவை
Investors should monitor the market share capture in the diabetes and obesity segment, as this affordable pricing could drive significant volume growth. This launch marks a major milestone in Alkem's transition toward a stronger chronic portfolio.
Alkem Labs Receives EU GMP Certificate for Daman Facility Valid for 3 Years
Alkem Laboratories has received a Certificate of GMP Compliance from the Malta Medicines Authority for its manufacturing facility located in Daman, India. This certification follows a successful inspection conducted in December 2025. The certificate is valid for a period of three years, effective from December 9, 2025. This regulatory approval is a significant step as it ensures the facility meets European standards for pharmaceutical manufacturing, facilitating exports to the EU market.
முக்கிய அம்சங்கள்
Received EU GMP compliance certificate from Malta Medicines Authority for the Daman plant.The certification is valid for a 3-year period starting from December 9, 2025.Follows a successful inspection previously intimated on December 10, 2025.Ensures continued access to the European Union market for products manufactured at this site.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory milestone that de-risks the company's European export business. No immediate action is required, but it reinforces confidence in Alkem's manufacturing quality standards.
Alkem Labs to Invest ₹533 Crore in New Greenfield Formulation Facility in Ujjain
Alkem Laboratories has received an allotment letter for 30 acres of land in Ujjain, Madhya Pradesh, to set up a new greenfield formulation manufacturing facility. The Board of Directors has approved a total investment of up to INR 533 crores for this project. The capital expenditure will be deployed in a phased manner to enhance the company's production capacity. This expansion is a strategic move to strengthen Alkem's domestic manufacturing footprint and support long-term growth.
முக்கிய அம்சங்கள்
Allotment of 30 acres of land in DMIC Vikram Udyogpuri Limited, Phase-2, UjjainBoard approval for a capital investment of up to INR 533 croresProject involves setting up a greenfield formulation manufacturing facilityInvestment to be executed in a phased manner to manage capital allocation
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive indicator of the company's growth trajectory and capacity expansion. Monitor the execution timeline and the impact of this capex on the company's debt-to-equity ratio and future margins.
Alkem Labs Receives EU GMP Compliance Certificate for Baddi Manufacturing Facility
Alkem Laboratories has received a Certificate of GMP Compliance from the German Health Authority for its manufacturing plant located in Baddi, India. This certification follows a successful inspection conducted between November 4 and November 10, 2025. The certificate is valid for a period of three years from the date of inspection, ensuring the facility meets European standards for human medicines. This regulatory clearance is crucial for the company's ability to supply pharmaceutical products to the European market.
முக்கிய அம்சங்கள்
Received 'Certificate of GMP Compliance' from the Department of Pharmacy (Human Medicines) – Germany.The inspection was conducted at the Baddi, India facility from 04th to 10th November 2025.The compliance certificate is valid for a period of 3 years from the date of inspection.The approval follows the initial inspection intimation provided by the company on 10th November 2025.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that de-risks the company's European export potential from the Baddi site. No immediate action is required, but this reinforces Alkem's strong regulatory compliance track record.
Alkem Labs Subsidiary Executes SPA to Acquire 51-55% Stake in Swiss Firm Occlutech Holding AG
Alkem Laboratories' subsidiary, Alkem Medtech, has officially signed a Share Purchase Agreement to acquire a controlling stake in Switzerland-based Occlutech Holding AG. The acquisition involves purchasing between 51% and 55% of the total issued equity share capital. This move follows the initial announcement made on February 13, 2026, signaling progress in Alkem's expansion into the medical technology sector. The transaction marks a significant step in Alkem's inorganic growth strategy in international markets.
முக்கிய அம்சங்கள்
Alkem Medtech to acquire a minimum of 51% and a maximum of 55% equity in Occlutech Holding AGOcclutech Holding AG is a Swiss-incorporated company specializing in medical technologyThe Share Purchase Agreement (SPA) was executed on March 06, 2026The acquisition is being executed through Alkem's wholly-owned subsidiary, Alkem Medtech Private Limited
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic diversification into the high-growth medical devices segment. Monitor for future disclosures regarding the acquisition valuation and its impact on the company's consolidated debt and margins.
Alkem Laboratories Releases Strategic Roadmap Recording for MedTech Division
Alkem Laboratories has officially released the video recording of its investor meet focused on the strategic way forward for Alkem MedTech. The disclosure, dated February 20, 2026, provides transparency into the company's future plans for its medical technology vertical. This meeting is significant as it outlines how the company intends to diversify beyond traditional pharmaceuticals. Investors can access the full recording via the company's website to evaluate the growth potential of this specific business segment.
முக்கிய அம்சங்கள்
Official recording of the 'Investor meet on Alkem MedTech’s strategic way forward' is now public.The meeting focused specifically on the future growth drivers and strategy for the MedTech division.Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) 2015.Strategic updates for the MedTech arm indicate a focus on business diversification and long-term value creation.
👀 கவனிக்க வேண்டியவை
Investors should review the recording to understand the capital allocation and revenue expectations for the MedTech business. Monitor the segment's progress as a potential catalyst for valuation rerating beyond the core pharma business.
Alkem MedTech to Acquire 51-55% Stake in Occlutech Holding AG for €180.70 Million
Alkem Laboratories' subsidiary, Alkem MedTech, has executed a binding term sheet to acquire a majority stake (51-55%) in Occlutech Holding AG for an equity value of €180.70 million (approx. ₹19,516 million). Occlutech is a leading global player in the structural heart occluder market, ranking 2nd in Europe and 3rd globally, with 2025 net sales of €50 million. This acquisition provides Alkem with a robust global platform, including 200+ patents and a presence in high-barrier markets like the US, EU, and Japan. The transaction is expected to close by June 2026 and will be funded entirely through internal accruals and existing cash balances.
முக்கிய அம்சங்கள்
Acquisition of 51-55% stake in Occlutech Holding AG at an equity value of €180.70 million (₹19,516 million).Occlutech reported €50 million in net sales for 2025 with a 14% CAGR from 2021-2025.Strategic entry into the $680 billion global MedTech market, specifically targeting the high-margin cardiovascular and musculoskeletal segments.Alkem MedTech aims for a 10% market share in the Indian large joints market within 5 years, targeting 250,000+ implants.Transaction includes a strong R&D pipeline with US FDA approval for PFO occluders expected by June 2027.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant strategic pivot towards high-margin medical technology that diversifies Alkem's traditional pharma portfolio. Monitor the successful integration of Occlutech and the progress of US FDA approvals for their pipeline products as key valuation re-rating triggers.
Alkem MedTech to Acquire 51-55% Stake in Occlutech for €180.7 Million
Alkem Laboratories' subsidiary, Alkem MedTech, has executed a binding term sheet to acquire a 51-55% stake in Occlutech Holding AG for an equity value of €180.70 million (approx. ₹19,516 million). Occlutech is a global leader in the structural heart occluder market, ranking #2 in Europe and #3 globally, with 2025 sales of €50 million. The acquisition will be funded through internal accruals and is expected to close by June 2026, providing Alkem a global platform in the cardiovascular space. Simultaneously, Alkem's orthopedic division is scaling rapidly, reporting over 50% quarter-on-quarter growth in implants.
முக்கிய அம்சங்கள்
Acquisition of 51-55% stake in Occlutech Holding AG at an equity value of €180.70 million (~₹19,516 million)Occlutech reported €50 million in sales for 2025 with a 14% CAGR from 2021-2025Alkem MedTech targets 250,000+ orthopedic implants and a 10% Indian market share by the 5th yearTransaction to be funded entirely via internal accruals with expected completion by June 2026Alkem Group reported FY24-25 Revenue of ₹129,645 million and EBITDA of ₹25,122 million
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic pivot into high-margin MedTech, diversifying Alkem's portfolio beyond traditional generics. Monitor the successful integration of Occlutech and its upcoming US FDA approval for PFO occluders expected in June 2027.
Alkem Labs Q3 FY26 Revenue Up 10.7% to ₹3,737 Cr; Announces Strategic MedTech Acquisition
Alkem Laboratories reported a steady Q3 FY26 with revenue growing 10.7% YoY to INR 37,368 million, driven by a robust 26.6% growth in international markets. The company announced a significant strategic entry into the MedTech space through the acquisition of Occlutech, targeting INR 1,000 crore in revenue from this segment within 3-5 years. While domestic growth was a modest 5.5% due to a high base effect, the company outperformed the Indian Pharmaceutical Market (IPM) in key therapies like anti-infectives and vitamins. EBITDA margins remained healthy at 22.2%, despite an exceptional charge of INR 528 million related to new labour codes.
முக்கிய அம்சங்கள்
Total revenue increased 10.7% YoY to INR 37,368 million, with international sales surging 26.6% to INR 12,157 million.EBITDA grew 9% YoY to INR 8,280 million with a margin of 22.2%.Management targets MedTech revenue of INR 1,000 crore with 25% EBITDA margins in the next 4-5 years.Outperformed IPM in 6 therapies, notably growing 2x the market in Vitamins and 1.4x in Anti-infectives.Net profit stood at INR 6,360 million, impacted by a INR 528 million exceptional item for Labour Code compliance.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of the Occlutech acquisition as it represents a high-margin, technology-led growth lever for the company. The stock remains a strong play on domestic market leadership and expanding international footprint.
Alkem Subsidiary Enzene Receives USFDA Form 483 with 6 Observations for Pune Facility
Alkem Laboratories' subsidiary, Enzene Biosciences, underwent a USFDA Pre-Approval Inspection (PAI) at its Chakan, Pune facility which concluded on February 13, 2026. The inspection resulted in the issuance of a Form 483 with 6 procedural observations. Importantly, the facility received zero observations related to data integrity, which is a critical metric for regulatory compliance. The company is currently preparing a response to address these observations within the stipulated timeline.
முக்கிய அம்சங்கள்
USFDA completed a Pre-Approval Inspection (PAI) at the Chakan, Pune facility on February 13, 2026The inspection concluded with a Form 483 containing 6 procedural observationsZero observations were reported regarding data integrity, validating the subsidiary's quality systemsEnzene Biosciences is a subsidiary of Alkem Laboratories LimitedThe company has initiated corrective and preventive actions to address the USFDA's findings
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to resolve these 6 procedural observations promptly to secure final approval. The absence of data integrity issues is a positive sign, reducing the likelihood of more severe regulatory escalations like a Warning Letter.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
